RT Journal Article SR Electronic T1 Human Epidermal Growth Factor Receptor 2-positive Primary Adenocarcinoma in the Cervical Oesophagus: A Case Report JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 2297 OP 2303 DO 10.21873/invivo.12503 VO 35 IS 4 A1 TOMO HORINOUCHI A1 NAOYA YOSHIDA A1 CHIHIRO MATSUMOTO A1 YOSHIHIRO HARA A1 TASUKU TOIHATA A1 MASAAKI IWATSUKI A1 YOSHIFUMI BABA A1 YUJI MIYAMOTO A1 HIDEO BABA YR 2021 UL http://iv.iiarjournals.org/content/35/4/2297.abstract AB Background/Aim: Cervical oesophageal adenocarcinoma (COA) is extremely rare. We present a case of human epidermal growth factor receptor 2 (HER2)-positive COA that showed repeated recurrences despite multidisciplinary treatments. Case Report: A 49-year-old male was diagnosed with clinical stage IVA COA that originated from ectopic gastric mucosa. He initially underwent definitive chemoradiotherapy (CRT) (60.0 Gy/30 fractions, 5-fluorouracil, and cisplatin). Two months after CRT, the right supraclavicular lymph node (LN) reenlarged and salvage lymphadenectomy was performed. Immunohistochemical staining revealed a HER2-positive adenocarcinoma. Four months after lymphadenectomy, multiple metastases in the mediastinal LNs and lungs were detected, and S-1, oxaliplatin and trastuzumab were administered. Four months after chemotherapy, the patient presented with new liver metastasis. Further metastasis was prevented by Nivolumab treatment for four months. Conclusion: HER2-positive COA may be more aggressive and may require further intensive treatments. This literature review may be helpful in determining treatment strategies for COA.